2010
A breakthrough in Hodgkin's disease
DeVita V. A breakthrough in Hodgkin's disease. Nature Reviews Clinical Oncology 2010, 7: 179-179. PMID: 20354537, DOI: 10.1038/nrclinonc.2010.36.Peer-Reviewed Original Research
1994
Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Longo D, Duffey P, Jaffe E, Raffeld M, Hubbard S, Fisher R, Wittes R, DeVita V, Young R. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. Journal Of Clinical Oncology 1994, 12: 2153-9. PMID: 7523607, DOI: 10.1200/jco.1994.12.10.2153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinCombined Modality TherapyCyclophosphamideCytarabineDisease-Free SurvivalDoxorubicinEtoposideFemaleFollow-Up StudiesHumansLymphoma, Non-HodgkinMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazinePrognosisRemission InductionSurvival RateVincristineConceptsAdvanced stage diseaseProMACE-MOPPProMACE-CytaBOMBurkitt's lymphomaLocalized diseaseComplete responseInvolved-field radiation therapyCombination chemotherapy programsOverall survival rateEfficacy of cyclophosphamideTreatment of patientsHigh-grade lymphomaMedian followComplete remissionIntercurrent illnessAdult patientsChemotherapy programCombination chemotherapyOverall survivalAggressive lymphomaRadiation therapyPatientsLymphomaSurvival rateDisease
1993
Lymphomas.
Kwak L, DeVita V, Longo D. Lymphomas. 1993, 14: 383-426. PMID: 8312110.Peer-Reviewed Original Research
1992
Lymphomas.
Longo D, DeVita V. Lymphomas. 1992, 13: 349-403. PMID: 1389915.Peer-Reviewed Original Research
1991
Lymphomas.
Longo D, Devita V. Lymphomas. 1991, 12: 347-93. PMID: 1931450.Peer-Reviewed Original Research
1988
Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.
Surbone A, Longo D, DeVita V, Ihde D, Duffey P, Jaffe E, Solomon D, Hubbard S, Young R. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. Journal Of Clinical Oncology 1988, 6: 1832-7. PMID: 3199167, DOI: 10.1200/jco.1988.6.12.1832.Peer-Reviewed Original ResearchConceptsResidual abdominal massesClinical complete remissionAbdominal massAggressive lymphomaNational Cancer InstituteStable residual massComplete remissionCombination chemotherapyPathologic evaluationFull-dose combination chemotherapyResidual massSubsequent tumor necrosisViable lymphoma cellsEvidence of diseaseMonths of chemotherapyInitial tumor sizeRestaging laparotomyBulky diseaseNegative laparotomyDisseminated diseaseIntraabdominal diseaseMost patientsSurgical explorationResidual tumorResidual diseaseThe role of chemotherapy in diffuse aggressive lymphomas.
DeVita V, Hubbard S, Young R, Longo D. The role of chemotherapy in diffuse aggressive lymphomas. Seminars In Hematology 1988, 25: 2-10. PMID: 3041598.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsDrug EvaluationHumansLymphoma, Non-HodgkinPrognosisConceptsDiffuse aggressive lymphomasEarly-stage diseaseCombination chemotherapyAggressive lymphomaDose intensityNew combination chemotherapy programScheduling of drugsDurable complete remissionRole of chemotherapyCombination chemotherapy programsImportant prognostic factorEnd of treatmentComplete remissionStage diseaseChemotherapy programPrognostic factorsSubsequent radiotherapyRisk factorsPrimary treatmentAdditional drugsChemotherapyOld drugsAdvanced stageLymphomaRadiotherapy
1986
The effect of combined modality therapy on local control and survival
DeVita V, Lippman M, Hubbard S, Ihde D, Rosenberg S. The effect of combined modality therapy on local control and survival. International Journal Of Radiation Oncology • Biology • Physics 1986, 12: 487-501. PMID: 3009367, DOI: 10.1016/0360-3016(86)90056-8.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsAnus NeoplasmsBreast NeoplasmsCarcinoma, Small CellClinical Trials as TopicCombined Modality TherapyFemaleHumansKidney NeoplasmsLung NeoplasmsLymphomaNeoplasm MetastasisNeoplasm Recurrence, LocalNeoplasmsPrognosisSarcomaSoft Tissue NeoplasmsWilms TumorConceptsLocal controlSystemic treatmentTumor typesPresence of micrometastasesEffective systemic therapyTumor cell numberLocal control measuresModality therapySystemic therapyCommon cancerMetastatic cancerLESS surgeryRadiation therapyTherapeutic programMetastatic processMicrometastasesTherapySurvivalSystemic componentCell numberTumorsMetastasis genesCancerSubstantial numberInverse relationship
1985
Renal involvement in diffuse aggressive lymphomas: results of treatment with combination chemotherapy.
Geffen D, Fisher R, Longo D, Young R, DeVita V. Renal involvement in diffuse aggressive lymphomas: results of treatment with combination chemotherapy. Journal Of Clinical Oncology 1985, 3: 646-53. PMID: 3998781, DOI: 10.1200/jco.1985.3.5.646.Peer-Reviewed Original ResearchConceptsNormal renal functionSerum creatinine levelsRenal involvementDiffuse aggressive lymphomasRenal functionCombination chemotherapyCreatinine levelsAggressive lymphomaElevated serum creatinine levelInitial local controlRecurrent renal diseaseEvidence of diseaseSite of recurrenceResults of treatmentComplete remissionDisseminated diseaseRenal diseaseSystemic diseaseHodgkin's lymphomaComplete resolutionRadiographic criteriaPatientsLocal controlLymphomaChemotherapy
1984
Prolonged initial remission in patients with nodular mixed lymphoma.
Longo D, Young R, Hubbard S, Wesley M, Fisher R, Jaffe E, Berard C, DeVita V. Prolonged initial remission in patients with nodular mixed lymphoma. Annals Of Internal Medicine 1984, 100: 651-6. PMID: 6370065, DOI: 10.7326/0003-4819-100-5-651.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCyclophosphamideDoxorubicinEtoposideFemaleHumansLeucovorinLymphoma, FollicularMaleMechlorethamineMethotrexateMiddle AgedNeoplasm StagingPrednisoneProcarbazinePrognosisRetrospective StudiesTime FactorsVincristineConceptsNodular mixed lymphomaComplete response rateMixed lymphomaComplete respondersInitial remissionMedian survivalResponse rateOverall complete response ratePrimary treatment regimensBone marrow involvementLactate dehydrogenase levelsNational Cancer InstituteAverage remissionB symptomsComplete remissionFirst remissionMarrow involvementShorter survivalTreatment regimensDehydrogenase levelsRemissionPatientsStage ICancer InstituteLymphoma
1983
Progress in cancer management. Keynote address
Devita V. Progress in cancer management. Keynote address. Cancer 1983, 51: 2401-2409. PMID: 6342749, DOI: 10.1002/1097-0142(19830615)51:12+<2401::aid-cncr2820511302>3.0.co;2-7.Peer-Reviewed Original ResearchConceptsCancer managementUtility of radiotherapyUse of radiotherapyCancer cure ratesWorld War IIEradication of cancerManagement of cancerPrime therapeutic targetFirst chemotherapyNational Cancer ActBlood transfusionLocal recurrenceMedical oncologistsTreatment failureRecurrent cancerCure rateWar IIEffective treatmentTherapeutic targetPatientsRadiotherapySurgerySuch toxicitySerious cancersCancerThe james ewing lecture. The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer
Devita V. The james ewing lecture. The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer. Cancer 1983, 51: 1209-1220. PMID: 6825044, DOI: 10.1002/1097-0142(19830401)51:7<1209::aid-cncr2820510707>3.0.co;2-j.Peer-Reviewed Original Research
1982
Malignant lymphoma II. Prognostic factors and response to treatment of 473 patients at the national cancer institute
Anderson T, Devita V, Simon R, Berard C, Canellos G, Garvin A, Young R. Malignant lymphoma II. Prognostic factors and response to treatment of 473 patients at the national cancer institute. Cancer 1982, 50: 2708-2721. PMID: 7139564, DOI: 10.1002/1097-0142(19821215)50:12<2708::aid-cncr2820501203>3.0.co;2-g.Peer-Reviewed Original ResearchConceptsHistologic typeDiffuse histologic typeComplete responseNational Cancer InstitutePrognostic factorsLymphoma patientsLymphocytic lymphomaCancer InstituteHigh complete response rateDiffuse lymphoma patientsModern radiotherapeutic techniquesNodular lymphocytic lymphomaNodular lymphoma patientsSimilar treatment regimensComplete response rateImportant prognostic factorStage of diseaseCS ICS IIICS IVB symptomsCombination chemotherapyIV patientsHistologic subtypePatient sexUndifferentiated non‐Hodgkin'S lymphomas (Burkitt's and non‐Burkitt's types). The relevance of making this histologic distinction
Miliauskas J, Berard C, Young R, Garvin A, Edwards B, Devita V. Undifferentiated non‐Hodgkin'S lymphomas (Burkitt's and non‐Burkitt's types). The relevance of making this histologic distinction. Cancer 1982, 50: 2115-2121. PMID: 7127252, DOI: 10.1002/1097-0142(19821115)50:10<2115::aid-cncr2820501024>3.0.co;2-9.Peer-Reviewed Original ResearchConceptsBurkitt's lymphomaMedian ageStage IVPrimary siteHistologic distinctionIntra-abdominal involvementFive-year survivalNational Cancer InstituteMedian survivalBurkitt's typeRetrospective studyHodgkin's lymphomaPatient populationLonger survivalCancer InstituteLymphomaPatientsSurvivalDiseaseMonthsAgePresentationYearsCases
1981
Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma.
Fisher R, Hubbard S, DeVita V, Berard C, Wesley R, Cossman J, Young R. Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood 1981, 58: 45-51. PMID: 7236892, DOI: 10.1182/blood.v58.1.45.bloodjournal58145.Peer-Reviewed Original ResearchConceptsLong-term survivalHuge abdominal massGastrointestinal involvementAbdominal massCurrent therapiesExcellent long-term survivalBone marrow statusBone marrow involvementSubset of patientsCases of diffuseMarrow statusConstitutional symptomsMarrow involvementMedian survivalHepatic involvementPrognostic factorsClinical factorsUndifferentiated lymphomaMale sexPatient survivalSerum LDHHistopathologic materialPatient groupPoor prognosisClinical trialsNatural history of malignant lymphomas with divergent histologies at staging evaluation
Fisher R, Jones R, Devita V, Simon R, Garvin A, Berard C, Young R. Natural history of malignant lymphomas with divergent histologies at staging evaluation. Cancer 1981, 47: 2022-2025. PMID: 7226096, DOI: 10.1002/1097-0142(19810415)47:8<2022::aid-cncr2820470820>3.0.co;2-v.Peer-Reviewed Original ResearchConceptsDifferent histologic diagnosesHistologic diagnosisNatural historyStaging evaluationMalignant lymphomaDiffuse patternNodular patternTissue sitesComplete response rateInitial staging evaluationNational Cancer InstituteMultiple tissue sitesMedian survivalMedical recordsCancer InstituteDivergent histologyPatientsBiopsyResponse ratePlanning treatmentUnique natural historyDiagnosisMonthsLymphomaTreatmentThe consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky memorial lecture
Devita V. The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky memorial lecture. Cancer 1981, 47: 1-13. PMID: 6970069, DOI: 10.1002/1097-0142(19810101)47:1<1::aid-cncr2820470102>3.0.co;2-2.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseLong-term adverse consequencesPresence of symptomsNational Cancer InstituteMOPP programComplete remissionNodular sclerosisHistologic subtypeImmunosuppressive drugsNational mortalityEffective chemotherapyDrug treatmentCancer InstituteChemotherapyDiseaseCarcinogenic effectsAdverse effectsYoung populationMOPPAdverse consequencesImportant negative influenceRemissionSclerosisPatientsPrognosis
1980
Non-Hodgkin's lymphomas in leukemic phase: Clinicopathologic correlations
Come S, Jaffe E, Andersen J, Mann R, Johnson B, DeVita V, Young R. Non-Hodgkin's lymphomas in leukemic phase: Clinicopathologic correlations. The American Journal Of Medicine 1980, 69: 667-674. PMID: 7001897, DOI: 10.1016/0002-9343(80)90416-7.Peer-Reviewed Original ResearchConceptsPeripheral blood involvementBlood involvementHistologic subtypeLeukemic phaseAdult lymphoblastic lymphomaDiffuse large cell lymphomaNon-Hodgkin lymphomaLarge cell lymphomaHomogeneous clinical pictureTypes of NHLLymphoblastic lymphomaRappaport classificationClinical pictureClinicopathologic entityHodgkin's lymphomaNodular lymphomaUnresponsive diseaseClinicopathologic correlationLymphocytic lymphomaClinical subtypesLeukemic conversionCell lymphomaCytologic featuresHigh riskPredominant cellsCancer, the Curable Diseases
DeVita V, Kershner L. Cancer, the Curable Diseases. Journal Of The American Pharmacists Association 1980, 20: 16-22. PMID: 6155779, DOI: 10.1016/s0160-3450(15)32990-1.Peer-Reviewed Original Research
1978
Clinical Relevance of the Histopathological Subclassification of Diffuse Histiocytic Lymphoma
Strauchen J, Young R, Devita V, Anderson T, Fantone J, Berard C. Clinical Relevance of the Histopathological Subclassification of Diffuse Histiocytic Lymphoma. New England Journal Of Medicine 1978, 299: 1382-1387. PMID: 362206, DOI: 10.1056/nejm197812212992503.Peer-Reviewed Original ResearchConceptsComplete response rateDiffuse histiocytic lymphomaHistopathological subclassificationExcellent prognosisIntermediate prognosisBetter prognosisPoor prognosisHistiocytic lymphomaMorphologic subclassificationHistopathological categoriesHeterogeneous diseaseClinical relevancePrognosisResponse rateMorphologic featuresLymphomaChemotherapyPatientsTumorsSubclassificationSurvivalDifferencesDisease